News | Magnetic Resonance Imaging (MRI) | August 22, 2016

Researchers say non-invasive technique avoids biopsies, makes research and treatment easier

NASH, nonalcoholic steatohepatitis, MRI, MRI-PDFF, University of California San Diego study

August 22, 2016 — Researchers at the University of California San Diego School of Medicine have found that a form of magnetic resonance imaging (MRI) corresponds with histological responses in patients with nonalcoholic steatohepatitis (NASH). The MRI technique in question non-invasively measures fat density in the liver.

The finding, published in the journal Therapeutic Advances in Gastroenterology, suggests the imaging technique can be useful in future NASH clinical trials and in treatment.

NASH is an advanced form of nonalcoholic fatty liver disease (NAFLD), which occurs when fat accumulates in liver cells due to causes other than excessive alcohol use. The precise cause is not known, but diet and genetics play substantial roles. The condition is relatively common. NAFLD occurs in roughly 20 percent of non-obese persons and in more than 60 percent of obese persons.

NAFLD often has no symptoms, but can progress to NASH and, ultimately, to cirrhosis or liver cancer.

“NAFLD and NASH are invisible diseases. In most cases, adverse effects are not noticeable until the disease is well-advanced,” said senior author Rohit Loomba, M.D., professor of medicine at UC San Diego School of Medicine and director of the Nonalcoholic Fatty Liver Disease Research Center at UC San Diego Health. “The ability to accurately quantify liver fat content, without resorting to needle biopsies, represents a significant advance, in the lab and in the clinic.”

Loomba and colleagues in the NAFLD Translational Research Unit and Liver Imaging Group looked at how a form of MRI, called magnetic resonance imaging-estimated proton-density-fat-fraction (MRI-PDFF), compared to liver biopsies in 35 patients with confirmed NASH diagnoses. Some patients received treatment for their condition, some received a placebo. All were assessed with both techniques before and after the treatment period.

The researchers found that a 29 percent reduction in liver fat, as measured by MRI-PDFF, translated to a clinically important improvement in liver histology. “MRI-PDFF has the potential to be a cost-effective and convenient method for liver fat quantification. It requires only a single, 20-second breath hold and an estimated time of about five minutes in an MRI scanner,” said Loomba.

Study authors noted that further external validation by independent research groups is needed.

Co-authors include: Janki Patel, Rikki Bettencourt, Jeffrey Cui, Joanie Salotti, Jonathan Hooker, Archana Bhatt, Carolyn Hernandez, Phirum Nguyen, Hamed Aryafar, Mark Valasek, William Haufe, Catherine Hooker, Lisa Richards, and Claude B. Sirlin, all at UC San Diego.

Funding for this research came, in part, from Atlantic Philanthropies, Inc., the John A. Hartford Foundation, OH, the Association of Specialty Professors, the American Gastroenterological Association and the National Institutes of Health (grant K23-DK090303).

For more information: www.tag.sagepub.com


Related Content

News | Radiology Business

April 4, 2024 — FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging ...

Time April 04, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | FDA

March 27, 2024 — SyntheticMR announced that its next-generation imaging solution, SyMRI 3D, has received FDA 510(k) ...

Time March 27, 2024
arrow
News | Artificial Intelligence

March 1, 2024 — Royal Philips, a global leader in health technology, and magnetic resonance imaging (MRI) software ...

Time March 01, 2024
arrow
News | Cardiac Imaging

February 12, 2024 — According to the American Journal of Roentgenology (AJR), free-breathing cine-deep learning (DL) may ...

Time February 12, 2024
arrow
News | Radiology Business

January 25, 2024 — Esaote Group, a leading Italian innovator in medical imaging, today unveiled its new brand identity ...

Time January 25, 2024
arrow
News | Artificial Intelligence

January 23, 2024 — Quibim announced it has added an industry-leading cancer detection capability to its prostate tool ...

Time January 22, 2024
arrow
News | Artificial Intelligence

December 22, 2023 — Quibim, a company pioneering imaging biomarkers for Precision Medicine that has created AI-based ...

Time December 22, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

December 20, 2023 — Terran Biosciences, Inc., a biotech platform company developing therapeutics and technologies for ...

Time December 20, 2023
arrow
News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
Subscribe Now